BioStock: RhoVac receives approval for long-term follow-up of phase I/II study
The cancer immunotherapy company RhoVac is currently conducting a phase IIb study with RV001, the company’s candidate for the treatment of prostate cancer. Yesterday it was announced that the company has received approval for a study aimed at expanding knowledge about the drug candidate’s long-term effects, through a long-term follow-up of patients who participated in a previous clinical phase I/II study. The treatment part of that study was completed in 2018 and the company has now received approval for a long-term follow-up of the study participants. BioStock contacted Anders Månsson, CEO of RhoVac, to find out more.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se